Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.56 |
| ▸ | HTR3B | O95264 | 3/20 | 0.56 |
| ▸ | HTR3A | P46098 | 3/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | SORD | Q00796 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134359 | 0.91 | MEN1 (0.58) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL8486348 | 0.89 | HRH4 (0.60) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL3684916 | 0.89 | KDM4E (0.59) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL8130723 | 0.89 | SIGMAR1 (0.58) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| Oxalic Acid SCHEMBL8149109 | 0.87 | HRH4 (0.51) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL8124752 | 0.87 | KMT2A (0.57) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| Oxalic Acid SCHEMBL8123092 | 0.86 | HRH4 (0.53) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL8130421 | 0.85 | HRH4 (0.56) | HRH4ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL3684760 | 0.85 | HTR3E (0.53) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL8110649 | 0.85 | KMT2A (0.56) | HRH4ALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025097-B1 | 1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4? RECEPTOR SUBTYPE LIGANDS | NEUROGEN CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1025097-B1 | 1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4? RECEPTOR SUBTYPE LIGANDS | NEUROGEN CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| CN-1191248-C | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2005-03-02 | — | — | CN | disclosed |
| US-6384224-B2 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASE | NEUROGEN CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-6384224-B2 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASE | NEUROGEN CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6331629-B1 | TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6331629-B1 | TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-12-18 | — | — | US | disclosed |
| CN-1283195-A | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2001-02-07 | — | — | CN | disclosed |
| US-6040448-A | USEFUL FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES. | NEUROGEN CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| EP-0970054-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0970054-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| US-6008352-A | USEFUL IN TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| US-6008352-A | USEFUL IN TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999021850-A1 | 1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D4 RECEPTOR SUBTYPE LIGANDS | NEUROGEN CORPORATION (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998039301-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039301-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-09-11 | — | — | WO | disclosed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | DRD2, DRD4, DRD3 | HRH4 131/4885ALDH1A1 976/4885MAPT 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.